Charlotte
-
CRO Inclinix merges with clinical trials site operator PMG Research
Clinical research organization Inclinix is merging with PMG Research in the latest merger and acquisition […]
-
CHTP’s arthritis drug fails phase 2; now everything rides on Northera
Chelsea Therapeutics‘ (NASDAQ:CHTP) rheumatoid arthritis treatment failed in phase 2 clinical trials and leaves the […]
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Chelsea Therapeutics to modify Northera study, resubmit NDA in 2013
Chelsea Therapeutics (NASDAQ:CHTP), regrouping from orphan drug Northera’s failure to secure regulatory approval, now plans […]
-
CHTP might seek limited Northera approval, meets with FDA this month
Chelsea Therapeutics (NASDAQ:CHTP) won’t meet with regulators until later this month to discuss its orphan […]
-
CHTP’s Northera rejected; FDA seeks more data for the orphan drug
Chelsea Therapeutics‘s (NASDAQ:CHTP) drug candidate Northera failed in its bid to secure U.S. Food and […]
-
CHTP’s Northera expected to get FDA approval decision today
Northera, the Chelsea Therapeutics (NASDAQ:CHTP) compound developed to treat dizziness and fainting in Parkinson’s disease […]
-
FDA panel recommends approval for Chelsea Therapeutics’ Northera
Updated 7:29 p.m. Northera, the Chelsea Therapeutics (NASDAQ:CHTP) drug developed to treat dizziness and fainting […]
-
FDA review recommends no approval for CHTP’s Northera
Chelsea Therapeutics (NASDAQ:CHTP) CEO Simon Pedder’s recent defense of drug candidate Northera omitted a key […]
-
FDA raises safety concerns on Chelsea’s Northera for Parkinson’s patients
Chelsea Therapeutics (NASDAQ:CHTP) won’t meet with a U.S. Food and Drug Administration advisory committee to […]
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
CHTP submits $100M shelf filing ahead of FDA decision on Northera
Drug developer Chelsea Therapeutics (NASDAQ:CHTP) is expanding its financial cushion to the tune of $100 […]
-
Stock offering nets $22.1M for drug developer Chelsea Therapeutics
The stock offering that Chelsea Therapeutics (NASDAQ:CHTP) expected to bring in $19.2 million in fresh […]
-
Mobile software firm Novarus shifts focus to digital health apps
Digital health company Novarus Healthcare has a new name and a new top executive. Healthcare […]
-
Chelsea Therapeutics prices $19.2M stock offering
Chelsea Therapeutics (NASDAQ:CHTP) has priced its stock offering and aims to raise $19.2 million to […]
-
Chelsea Therapeutics to raise $19.7M for new drug launch and drug pipeline
Chelsea Therapeutics (NASDAQ:CHTP) is preparing for the launch of its first product — a drug […]
-
MedCath sells Texas hospital; just one facility left in MDTH portfolio
MedCath (NASDAQ:MDTH) has sold its stake in a Texas hospital, leaving the dissolving hospital operator […]
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
